ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies

Molecular Cancer Therapeutics

Volumn 15, Issue 11, 2016, Pages 2709-2721

  Flynn, Michael J ^a,b   Zammarchi, Francesca ^c   Tyrer, Peter C ^b   Akarca, Ayse U ^d   Janghra, Narinder ^d   Britten, Charles E ^c   Havenith, Carin E G ^c   Levy, Jean Noel ^b   Tiberghien, Arnaud ^b   Masterson, Luke A ^b   Barry, Conor ^b   D'Hooge, Francois ^b   Marafioti, Teresa ^d   Parren, Paul W H I ^e,f   Williams, David G ^b   Howard, Philip W ^b   Van Berkel, Patrick H ^c   Hartley, John A ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c ADC Therapeutics   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e GENMAB   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BENZODIAZEPINE DERIVATIVE; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; DIMER; DNA; DRUG ANTIBODY; HISTONE H2AX; IMMUNOGLOBULIN G1; INTERLEUKIN 2 RECEPTOR ALPHA; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; HISTONE; PYRROLE DERIVATIVE; PYRROLO(2,1-C)(1,4)BENZODIAZEPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; APOPTOSIS; ARTICLE; BINDING AFFINITY; BYSTANDER EFFECT; CELL VIABILITY; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY; DNA CROSS LINKING; DNA DAMAGE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; G2 PHASE CELL CYCLE CHECKPOINT; HEMATOLOGIC MALIGNANCY; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; INTERNALIZATION; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEMATOLOGIC NEOPLASMS; METABOLISM; PATHOLOGY; PRECLINICAL STUDY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZODIAZEPINES; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HEMATOLOGIC NEOPLASMS; HISTONES; HUMANS; IMMUNOCONJUGATES; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; PYRROLES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84995370839     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0233     Document Type: Article

References (48)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Strauchen JA, Breakstone BA. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am J Pathol 1987; 126: 506-12.
3. Sheibani K, Winberg CD, van de Velde S, Blayney DW, Rappaport H. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases. Am J Pathol 1987; 127: 27-37.
4. Dasanu CA. Newer developments in adult T-cell leukemia/lymphoma therapeutics. Expert Opin Pharmacother 2011; 12: 1709-17.
5. Shao H, Calvo KR, Gronborg M, Tembhare PR, Kreitman RJ, Stetler- Stevenson M, et al. Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria. Leuk Res 2013; 37: 401-9.
6. Guo Z, Wang A, Zhang W, Levit M, Gao Q, Barberis C, et al. PIM inhibitors target CD25-positiveAMLcells through concomitant suppression of STAT5 activation and degradation of MYC oncogene. Blood 2014; 124: 1777-89.
7. Srivastava MD, Srivastava A, Srivastava BI. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies. Leuk Lymphoma 1994; 12: 241-51.
8. Raziuddin S, Sheikha A, Abu-Eshy S, al-Janadi M. Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies. Cancer 1994; 73: 2426-31.
9. Yamauchi T, Matsuda Y, Takai M, Tasaki T, Tai K, Hosono N, et al. Early relapse is associated with high serum soluble interleukin-2 receptor after the sixth cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma. Anticancer Res 2012; 32: 5051-7.
10. Kadin ME, Pavlov IY, Delgado JC, Vonderheid EC. High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides. J Invest Dermatol 2012; 132: 703-10.
11. Nakase K, Kita K, Kyo T, Tsuji K, Katayama N. High serum levels of soluble interleukin-2 receptor in acute myeloid leukemia: Correlation with poor prognosis and CD4 expression on blast cells. Cancer Epidemiol 2012; 36: E306-9.
12. Yang ZZ, Grote DM, Ziesmer SC, Manske MK, Witzig TE, Novak AJ, et al. Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 2011; 118: 2809-20.
13. Pui CH, Ip SH, Kung P, Dodge RK, Berard CW, Crist WM, et al. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood 1987; 70: 624-8.
14. Ambrosetti A, Nadali G, Vinante F, Carlini S, Veneri D, Todeschini G, et al. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationshipwith clinical stage, tumor burden, and treatment outcome. Cancer 1993; 72: 201-6.
15. Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, et al. Prognostic index for acute- And lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol 2012; 30: 1635-40.
16. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, et al. Radioimmunotherapy of interleukin-2R alphaexpressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 1995; 86: 4063-75.
17. Dancey G, Violet J, Malaroda A, Green AJ, Sharma SK, Francis R, et al. A phase I clinical trial of CHT-25 a 131I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma. Clin Cancer Res 2009; 15: 7701-10.
18. Janik JE, Morris JC, O'Mahony D, Pittaluga S, Jaffe ES, Redon CE, et al. 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma. Proc Natl Acad Sci U S A 2015; 112: 13045-50.
19. Kreitman RJ, Wilson WH, White JD, Stetler-StevensonM, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622-36.
20. Kreitman RJ, Stetler-Stevenson M, Jaffe ES, Conlon KC, Steinberg SM, Wilson WH, et al. Complete remissions of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 and chemotherapy to block immunogenicity. Clin Cancer Res 2016; 22: 310-8
21. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-88.
22. Madhumathi J, Devilakshmi S, Sridevi S, Verma RS. Immunotoxin therapy for hematologic malignancies: Where are we heading? Drug Discov Today 2016; 21: 325-32.
23. Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I. Immunotoxins for leukemia. Blood 2014; 123: 2470-7.
24. Adair JR, Howard PW, Hartley JA,WilliamsDG, Chester KA. Antibody-drug conjugates - A perfect synergy. Expert Opin Biol Ther 2012; 12: 1191-206.
25. Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, et al. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res 2011; 17: 3794-802.
26. Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG, et al. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol 2010; 65: 833-8.
27. Kung SutherlandMS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013; 122: 1455-63.
28. Tiberghien AC, Levy J-N, Masterson LA, PatelNV, Adams LR, Corbett S, et al. Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload. ACS Med Chem Lett. Epub 24 May 2016. Available from: Http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.6b00062 [Accessed: 2016 Jun 30].
29. DAKO. QIFIKIT Code K0078: DK-2600 [Internet]; 2008[cited 14 April 2014]. Available from: Http://www.dako.com/uk/download.pdf? objectid=111993002
30. Riss TL, Moravec RA, Niles AL, Benink HA, Worzella TJ, Minor L, et al. Cell viability assays. In: Sittampalam GS, Coussens NP, Nelson H, Arkin M, AuldD, Austin C, et al. , editors. Assay guidance manual. Bethesda,MD: Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004.
31. Spanswick VJ, Hartley JM, Hartley JA. Measurement of DNA interstrand crosslinking in individual cells using the single cell gel electrophoresis (Comet) assay. Methods Mol Biol 2010; 613: 267-82.
32. Marafioti T, Jones M, Facchetti F, Diss TC, Du MQ, Isaacson PG, et al. Phenotype and genotype of interfollicular large B cells, a subpopulation of lymphocytes often with dendritic morphology. Blood 2003; 102: 2868-76.
33. Marafioti T, Pozzobon M, Hansmann ML, Delsol G, Pileri SA, Mason DY. Expression of intracellular signalingmolecules in classical and lymphocyte predominance Hodgkin disease. Blood 2004; 103: 188-93.
34. Wu J, Clingen PH, Spanswick VJ, Mellinas-Gomez M, Meyer T, Puzanov I, et al. gamma-H2AX foci formation as a pharmacodynamic marker of DNA damage produced by DNA cross-linking agents: Results from 2 phase I clinical trials of SJG-136 (SG2000). Clin Cancer Res 2013; 19: 721-30.
35. Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 2013; 24: 1256-63.
36. Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells invivo. Sci Transl Med 2015; 7: 302ra136.
37. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006; 17: 114-24.
38. Wolke C, Tadje J, Bukowska A, Tager M, Bank U, Ittenson A, et al. Assigning the phenotype of a natural regulatory T-cell to the human T-cell line, KARPAS-299. Int J Mol Med 2006; 17: 275-8.
39. Kawabata KC, Ehata S, Komuro A, Takeuchi K, Miyazono K. TGF-betainduced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20. Oncogene 2013; 32: 2096-106.
40. Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: Part 1: Cellular pharmacology, invitro and initial invivo antitumor activity. Cancer Res 2004; 64: 6693-9.
41. Clingen PH, De Silva IU, McHugh PJ, Ghadessy FJ, Tilby MJ, Thurston DE, et al. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1- c][1,4]benzodiazepine dimer SJG-136. Nucleic Acids Res 2005; 33: 3283-91.
42. Osawa T, Davies D, Hartley JA. Mechanism of cell death resulting from DNA interstrand cross-linking in mammalian cells. Cell Death Dis 2011; 2: E187.
43. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012; 12: 180-90.
44. Holter W, Goldman CK, Casabo L, Nelson DL, Greene WC, Waldmann TA. Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. J Immunol 1987; 138: 2917-22.
45. Herrmann F,Cannistra SA, LevineH,Griffin JD. Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med 1985; 162: 1111-6.
46. Riedel D, Lindemann A, Brach M, Mertelsmann R, Herrmann F. Granulocyte- macrophage colony-stimulating factor and interleukin-3 induce surface expression of interleukin-2 receptor p55-chain and CD4 by human eosinophils. Immunology 1990; 70: 258-61.
47. Maggiano N, Colotta F, Castellino F, Ricci R, Valitutti S, Larocca LM, et al. Interleukin-2 receptor expression in human mast cells and basophils. Int Arch Allergy Appl Immunol 1990; 91: 8-14.
48. Powell DJ, Felipe-Silva A, MerinoMJ, AhmadzadehM, Allen T, Levy C, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells invivo. J Immunol 2007; 179: 4919-28.